Prevention

SAN FRANCISCO — New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly injections already under review by the FDA.

A recent survey conducted by the HIV Medicine Association identified barriers to implementation of long-acting injectables for HIV prevention which included the need for prior authorization and funding issues.

A prevention bundle reduced inflammation, infections and hospitalizations among nursing home residents with peripherally inserted central catheters, according to a study.

Regardless of country-level income classification, medications for the secondary prevention of CVD remains underutilized and patients likely remain undertreated, researcher reported.

ORLANDO — Primary prevention programs for substance abuse should use strategies like those aimed at stress management and navigation of group dynamics, according to a speaker the Lifestyle Medicine Conference.

LIMA, Peru — Positive data continue to roll in for lenacapavir, the long-acting injectable that looks like a game-changer for HIV prevention.

LIMA, Peru — Healio is on site for the International AIDS Society’s HIV Research for Prevention Conference, which will take place from Oct. 6 to 10.

By addressing factors like health insurance coverage, internet access and income level, primary care providers can play an important role in suicide prevention, according to experts.

In June, Gilead Sciences announced that its investigational antiretroviral drug lenacapavir prevented 100% of new HIV infections during a phase 3 trial conducted among cisgender women in Africa.